<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>药春秋 | wechat-feeds</title><link>http://MzI0MDM2NTA4NQ.favicon.privacyhide.com/favicon.ico</link><description>医药行业一致性评价工作在如火如荼的进行中，作为行业的一份子，愿本愚公之念，出蝼蚁 之力，献寸光之策。</description><managingEditor> (hellodword)</managingEditor><pubDate>Fri, 16 Apr 2021 23:25:04 +0800</pubDate><image><url>http://MzI0MDM2NTA4NQ.favicon.privacyhide.com/favicon.ico</url><title>药春秋 | wechat-feeds</title><link>http://MzI0MDM2NTA4NQ.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>3月一致性评价：申报量回升，28过评品种决出首家…</title><link>https://mp.weixin.qq.com/s/quFamD30BkQHQZT6t2axlA</link><description></description><content:encoded><![CDATA[3月一致性评价：申报量回升，28过评品种决出首家…]]></content:encoded><pubDate>Fri, 16 Apr 2021 21:43:13 +0800</pubDate></item><item><title>潜力骨松症用药，原研一家独大，破局更待何时？</title><link>https://mp.weixin.qq.com/s/xrPBtfBpYh-BF2OEm1sltA</link><description></description><content:encoded><![CDATA[潜力骨松症用药，原研一家独大，破局更待何时？]]></content:encoded><pubDate>Fri, 16 Apr 2021 21:43:13 +0800</pubDate></item><item><title>第四十二批参比目录公示，62个新增（增补），8个不通过</title><link>https://mp.weixin.qq.com/s/R54BQUUvca29OceLBlBbIg</link><description></description><content:encoded><![CDATA[第四十二批参比目录公示，62个新增（增补），8个不通过]]></content:encoded><pubDate>Fri, 16 Apr 2021 21:43:13 +0800</pubDate></item><item><title>注意！这些药品将被暂停采购</title><link>https://mp.weixin.qq.com/s/2W6d9ID-4sQhFzknyg2rzw</link><description></description><content:encoded><![CDATA[注意！这些药品将被暂停采购]]></content:encoded><pubDate>Fri, 16 Apr 2021 21:43:13 +0800</pubDate></item><item><title>第五批国采报量开始，开标之日近在咫尺...</title><link>https://mp.weixin.qq.com/s/7FdvLryH5EvENT0IrRIEWg</link><description></description><content:encoded><![CDATA[第五批国采报量开始，开标之日近在咫尺...]]></content:encoded><pubDate>Thu, 15 Apr 2021 18:02:27 +0800</pubDate></item><item><title>（2021.4.15）最新一致性评价目录来了！</title><link>https://mp.weixin.qq.com/s/rPfwqm1xjEA492Zq0Pbu0Q</link><description></description><content:encoded><![CDATA[（2021.4.15）最新一致性评价目录来了！]]></content:encoded><pubDate>Thu, 15 Apr 2021 18:02:27 +0800</pubDate></item><item><title>知名大药企涉嫌垄断，被罚7.64亿元！</title><link>https://mp.weixin.qq.com/s/mbDiz6kgv6QaxFhDMJ0y9Q</link><description></description><content:encoded><![CDATA[知名大药企涉嫌垄断，被罚7.64亿元！]]></content:encoded><pubDate>Thu, 15 Apr 2021 18:02:27 +0800</pubDate></item><item><title>仿制药制剂：工艺研究和工艺验证</title><link>https://mp.weixin.qq.com/s/kO6QHM6Oyvin8ImvM57cHA</link><description></description><content:encoded><![CDATA[仿制药制剂：工艺研究和工艺验证]]></content:encoded><pubDate>Thu, 15 Apr 2021 18:02:27 +0800</pubDate></item><item><title>106个鼓励研发儿科用药，千亿市场迎来新机遇！</title><link>https://mp.weixin.qq.com/s/6S4BFo1QjDjSKPPuuLYkZQ</link><description></description><content:encoded><![CDATA[106个鼓励研发儿科用药，千亿市场迎来新机遇！]]></content:encoded><pubDate>Wed, 14 Apr 2021 21:35:39 +0800</pubDate></item><item><title>奥曲肽：40亿重磅多肽，国产“微球”正待酝酿</title><link>https://mp.weixin.qq.com/s/oBlF_7qJ9uwoOxZfFqU_2A</link><description></description><content:encoded><![CDATA[奥曲肽：40亿重磅多肽，国产“微球”正待酝酿]]></content:encoded><pubDate>Wed, 14 Apr 2021 21:35:39 +0800</pubDate></item><item><title>一批知名大品种降价了，降幅最高44.8%！</title><link>https://mp.weixin.qq.com/s/jDrqwhS_LU3JxBwSP5HZ4Q</link><description></description><content:encoded><![CDATA[一批知名大品种降价了，降幅最高44.8%！]]></content:encoded><pubDate>Wed, 14 Apr 2021 21:35:39 +0800</pubDate></item><item><title>儿科改良药“大热”，CDE发文：临床试验将规范化</title><link>https://mp.weixin.qq.com/s/U33tKY_MI98SEa-OcjCc5Q</link><description></description><content:encoded><![CDATA[儿科改良药“大热”，CDE发文：临床试验将规范化]]></content:encoded><pubDate>Wed, 14 Apr 2021 21:35:39 +0800</pubDate></item><item><title>（2021.4.13）最新过评名单，2品种首家冲线…</title><link>https://mp.weixin.qq.com/s/KD5DkCWKGG4ggU9jp9HN-g</link><description></description><content:encoded><![CDATA[（2021.4.13）最新过评名单，2品种首家冲线…]]></content:encoded><pubDate>Tue, 13 Apr 2021 21:40:04 +0800</pubDate></item><item><title>【项目合作】8款抗肿瘤药物，部分已完成BE</title><link>https://mp.weixin.qq.com/s/K5auYU1OlJYnmX9DyNKSHg</link><description></description><content:encoded><![CDATA[【项目合作】8款抗肿瘤药物，部分已完成BE]]></content:encoded><pubDate>Tue, 13 Apr 2021 21:40:04 +0800</pubDate></item><item><title>注意！这些注射剂价格存异、需调整</title><link>https://mp.weixin.qq.com/s/QtT2ToPtkmLhbCTFS7WcxQ</link><description></description><content:encoded><![CDATA[注意！这些注射剂价格存异、需调整]]></content:encoded><pubDate>Tue, 13 Apr 2021 21:40:04 +0800</pubDate></item><item><title>16品种BE技术指导原则或有新变动！</title><link>https://mp.weixin.qq.com/s/QOCfEYoqHxXMtI2ACypuog</link><description></description><content:encoded><![CDATA[16品种BE技术指导原则或有新变动！]]></content:encoded><pubDate>Tue, 13 Apr 2021 21:40:04 +0800</pubDate></item><item><title>潜力免疫抑制剂领域，头部品种大卖300亿元！</title><link>https://mp.weixin.qq.com/s/2TuVk6QiKf8RIifNxkTxcA</link><description></description><content:encoded><![CDATA[潜力免疫抑制剂领域，头部品种大卖300亿元！]]></content:encoded><pubDate>Mon, 12 Apr 2021 21:38:04 +0800</pubDate></item><item><title>省际联盟集采开启“新玩法”，中标平均价成“基准”？！</title><link>https://mp.weixin.qq.com/s/NOwLl83X2kkBe3YcQtjcbQ</link><description></description><content:encoded><![CDATA[省际联盟集采开启“新玩法”，中标平均价成“基准”？！]]></content:encoded><pubDate>Mon, 12 Apr 2021 21:38:04 +0800</pubDate></item><item><title>154个过评药，新增挂网采购</title><link>https://mp.weixin.qq.com/s/ooWDY-C4L0sykYxom_T0Fg</link><description></description><content:encoded><![CDATA[154个过评药，新增挂网采购]]></content:encoded><pubDate>Mon, 12 Apr 2021 21:38:04 +0800</pubDate></item><item><title>药品多晶型在仿制药中的应用</title><link>https://mp.weixin.qq.com/s/uHBuq0w2WC6q6dvjvrqrGA</link><description></description><content:encoded><![CDATA[药品多晶型在仿制药中的应用]]></content:encoded><pubDate>Mon, 12 Apr 2021 21:38:04 +0800</pubDate></item></channel></rss>